compound introduction
Peficitinib (ASP015K, JNJ-54781532)是一种口服具有生物活性的 JAK 抑制剂。 Information Peficitinib (ASP015K, JNJ-54781532) is an orally bioavailableJAKinhibitor. Phase 3. Targets JAK In vitro ASP015K suppresses the IL-2-induced proliferation of human T cells with greater potency than EPO-induced proliferation of human erythroleukemia cells. In human whole blood, ASP015K inhibits STAT5 phosphorylation (pSTAT5). In vivo In the rat AIA model, ASP015K (p.o.) significantly decreases paw swelling and ankle bone destruction score.
